NASDAQ:RARX - Ra Pharmaceuticals Stock Price, Price Target & More

$6.19 -0.07 (-1.12 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$6.19
Today's Range$6.07 - $6.26
52-Week Range$4.78 - $27.84
Volume117,195 shs
Average Volume252,954 shs
Market Capitalization$197.92 million
P/E Ratio-2.57
Dividend YieldN/A
Beta2.31

About Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals logoRa Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.

Receive RARX News and Ratings via Email

Sign-up to receive the latest news and ratings for RARX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RARX
CUSIPN/A
Phone617-401-4060

Debt

Debt-to-Equity RatioN/A
Current Ratio8.46%
Quick Ratio8.46%

Price-To-Earnings

Trailing P/E Ratio-2.57
Forward P/E Ratio-2.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.93 million
Price / Sales40.54
Cash FlowN/A
Price / CashN/A
Book Value$3.06 per share
Price / Book2.02

Profitability

EPS (Most Recent Fiscal Year)($2.41)
Net Income$-54,430,000.00
Net MarginsN/A
Return on Equity-61.37%
Return on Assets-55.28%

Miscellaneous

Employees63
Outstanding Shares32,290,000

How to Become a New Pot Stock Millionaire

Ra Pharmaceuticals (NASDAQ:RARX) Frequently Asked Questions

What is Ra Pharmaceuticals' stock symbol?

Ra Pharmaceuticals trades on the NASDAQ under the ticker symbol "RARX."

How were Ra Pharmaceuticals' earnings last quarter?

Ra Pharmaceuticals Inc (NASDAQ:RARX) posted its earnings results on Wednesday, March, 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.70) by $0.03. View Ra Pharmaceuticals' Earnings History.

When is Ra Pharmaceuticals' next earnings date?

Ra Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Ra Pharmaceuticals.

What price target have analysts set for RARX?

5 brokerages have issued twelve-month price objectives for Ra Pharmaceuticals' shares. Their forecasts range from $14.00 to $31.00. On average, they anticipate Ra Pharmaceuticals' share price to reach $22.00 in the next year. View Analyst Ratings for Ra Pharmaceuticals.

Are investors shorting Ra Pharmaceuticals?

Ra Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,700,188 shares, an increase of 52.2% from the February 28th total of 1,117,092 shares. Based on an average daily volume of 353,290 shares, the days-to-cover ratio is currently 4.8 days. Approximately 10.1% of the company's shares are short sold.

Who are some of Ra Pharmaceuticals' key competitors?

Who are Ra Pharmaceuticals' key executives?

Ra Pharmaceuticals' management team includes the folowing people:
  • Douglas A. Treco Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Jeffrey Johnston M.D., Senior Vice President, Chief Medical Officer
  • Alonso Ricardo Ph.D., Senior Vice President of Research & Development
  • Kerry Black, Executive Director, Operations
  • Edward T. Mathers, Board Member (Age 57)

When did Ra Pharmaceuticals IPO?

(RARX) raised $75 million in an IPO on Wednesday, October 26th 2016. The company issued 5,800,000 shares at $12.00-$14.00 per share. Credit Suisse, Jefferies and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey was co-manager.

Has Ra Pharmaceuticals been receiving favorable news coverage?

News stories about RARX stock have trended positive on Thursday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ra Pharmaceuticals earned a news impact score of 0.49 on Accern's scale. They also assigned media headlines about the company an impact score of 48.11 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Ra Pharmaceuticals?

Shares of RARX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ra Pharmaceuticals' stock price today?

One share of RARX stock can currently be purchased for approximately $6.19.

How big of a company is Ra Pharmaceuticals?

Ra Pharmaceuticals has a market capitalization of $197.92 million and generates $4.93 million in revenue each year. The company earns $-54,430,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Ra Pharmaceuticals employs 63 workers across the globe.

How can I contact Ra Pharmaceuticals?

Ra Pharmaceuticals' mailing address is 87 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA, 02140. The company can be reached via phone at 617-401-4060 or via email at [email protected]


MarketBeat Community Rating for Ra Pharmaceuticals (RARX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Ra Pharmaceuticals and other stocks. Vote "Outperform" if you believe RARX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ra Pharmaceuticals (NASDAQ:RARX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Ra Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.00, suggesting that the stock has a possible upside of 255.41%. The high price target for RARX is $31.00 and the low price target for RARX is $14.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.00$22.00$23.25$25.60
Price Target Upside: 255.41% upside218.38% upside186.68% upside71.70% upside

Ra Pharmaceuticals (NASDAQ:RARX) Consensus Price Target History

Price Target History for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ:RARX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018SunTrust BanksReiterated RatingBuyLowView Rating Details
3/15/2018BMO Capital MarketsLower Price TargetOutperform -> Outperform$34.00 -> $31.00HighView Rating Details
2/13/2018Credit Suisse GroupLower Price TargetOutperform -> Outperform$16.00 -> $14.00MediumView Rating Details
12/5/2017Royal Bank of CanadaReiterated RatingBuy$18.00HighView Rating Details
9/28/2017Jefferies GroupReiterated RatingBuy$25.00MediumView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Ra Pharmaceuticals (NASDAQ:RARX) Earnings History and Estimates Chart

Earnings by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ:RARX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.77)($0.57)($0.67)
Q2 20182($0.91)($0.49)($0.70)
Q3 20182($0.93)($0.50)($0.72)
Q4 20182($1.14)($0.52)($0.83)

Ra Pharmaceuticals (NASDAQ RARX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018        
3/14/2018Q4 2017($0.6970)($0.67)ViewN/AView Earnings Details
11/9/2017Q3 2017($0.62)($0.68)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.4950)($0.56)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.5820)($0.50)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.44)($0.73)ViewN/AView Earnings Details
11/29/2016Q3 2016($0.50)($14.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ra Pharmaceuticals (NASDAQ:RARX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ra Pharmaceuticals (NASDAQ RARX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 47.86%
Insider Trading History for Ra Pharmaceuticals (NASDAQ:RARX)
Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Ra Pharmaceuticals (NASDAQ RARX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/16/2018Enterprise Associates 13 L NewMajor ShareholderBuy2,000,000$6.00$12,000,000.00View SEC Filing  
2/14/2018Ra Capital Healthcare Fund LpMajor ShareholderBuy2,500,000$6.00$15,000,000.00View SEC Filing  
6/19/2017Bioventures Ltd NovartisMajor ShareholderSell56,420$21.29$1,201,181.80View SEC Filing  
6/7/2017Bioventures Ltd NovartisMajor ShareholderSell12,114$22.63$274,139.82View SEC Filing  
6/5/2017Bioventures Ltd NovartisMajor ShareholderSell19,647$23.38$459,346.86View SEC Filing  
6/1/2017Bioventures Ltd NovartisMajor ShareholderSell46,261$23.93$1,107,025.73View SEC Filing  
5/26/2017Bioventures Ltd NovartisMajor ShareholderSell5,353$25.14$134,574.42View SEC Filing  
5/24/2017Bioventures Ltd NovartisMajor ShareholderSell17,451$25.01$436,449.51View SEC Filing  
5/18/2017Bioventures Ltd NovartisMajor ShareholderSell9,019$25.50$229,984.50View SEC Filing  
5/17/2017Bioventures Ltd NovartisMajor ShareholderSell42,615$25.90$1,103,728.50View SEC Filing  
10/31/2016Harry R WellerMajor ShareholderBuy338,462$13.00$4,400,006.00View SEC Filing  
10/31/2016Rajeev M ShahDirectorBuy161,538$13.00$2,099,994.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ra Pharmaceuticals (NASDAQ RARX) News Headlines

Source:
DateHeadline
Zacks Investment Research Lowers Ra Pharmaceuticals (RARX) to SellZacks Investment Research Lowers Ra Pharmaceuticals (RARX) to Sell
www.americanbankingnews.com - April 18 at 7:30 PM
Ra Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from BrokeragesRa Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM
Ra Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.57 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - April 12 at 1:23 PM
Ra Pharmaceuticals (RARX) Upgraded to "Hold" by Zacks Investment ResearchRa Pharmaceuticals (RARX) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:55 PM
Ra Pharmaceuticals (RARX) Upgraded by Zacks Investment Research to "Hold"Ra Pharmaceuticals (RARX) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 8 at 5:55 PM
Short Interest in Ra Pharmaceuticals Inc (RARX) Grows By 52.2%Short Interest in Ra Pharmaceuticals Inc (RARX) Grows By 52.2%
www.americanbankingnews.com - March 30 at 4:01 AM
Ra Pharmaceuticals (RARX) Upgraded at Zacks Investment ResearchRa Pharmaceuticals (RARX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 29 at 5:16 PM
Zacks Investment Research Lowers Ra Pharmaceuticals (RARX) to HoldZacks Investment Research Lowers Ra Pharmaceuticals (RARX) to Hold
www.americanbankingnews.com - March 28 at 9:48 PM
Ra Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from AnalystsRa Pharmaceuticals Inc (RARX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 24 at 1:30 AM
Ra Pharmaceuticals Inc (RARX) Expected to Post FY2022 Earnings of $0.23 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Post FY2022 Earnings of $0.23 Per Share
www.americanbankingnews.com - March 19 at 9:48 AM
Ra Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($0.57) Per Share (RARX)Ra Pharmaceuticals Inc Expected to Post Q1 2018 Earnings of ($0.57) Per Share (RARX)
www.americanbankingnews.com - March 19 at 1:18 AM
Ra Pharmaceuticals (RARX) Given New $31.00 Price Target at BMO Capital MarketsRa Pharmaceuticals (RARX) Given New $31.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - March 15 at 5:25 PM
Ra Pharmaceuticals (RARX) Posts Quarterly  Earnings Results, Beats Estimates By $0.03 EPSRa Pharmaceuticals (RARX) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - March 15 at 1:56 PM
Ra Pharmaceuticals (RARX) Rating Reiterated by SunTrust BanksRa Pharmaceuticals (RARX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 15 at 11:54 AM
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate UpdateRa Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 5:28 PM
Ra Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.72 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - March 9 at 5:24 PM
Ra Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care ConferenceRa Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 7 at 9:46 AM
VHCP Management II LLC Sells 225,159 Shares of Ra Pharmaceuticals Inc (RARX)VHCP Management II LLC Sells 225,159 Shares of Ra Pharmaceuticals Inc (RARX)
www.americanbankingnews.com - March 6 at 10:50 AM
Ra Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN MeetingRa Pharmaceuticals to Present Design of RA101495 SC Phase 2 Clinical Trial in gMG at the 70th Annual AAN Meeting
finance.yahoo.com - March 1 at 4:40 PM
Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by AnalystsRa Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 27 at 1:52 AM
Citadel Advisors LLC Has $2.55 Million Holdings in Ra Pharmaceuticals Inc (RARX)Citadel Advisors LLC Has $2.55 Million Holdings in Ra Pharmaceuticals Inc (RARX)
www.americanbankingnews.com - February 26 at 12:02 PM
Ra Pharmaceuticals Inc (RARX) Major Shareholder Purchases $12,000,000.00 in StockRa Pharmaceuticals Inc (RARX) Major Shareholder Purchases $12,000,000.00 in Stock
www.americanbankingnews.com - February 21 at 6:12 PM
-$0.72 EPS Expected for Ra Pharmaceuticals Inc (RARX) This Quarter-$0.72 EPS Expected for Ra Pharmaceuticals Inc (RARX) This Quarter
www.americanbankingnews.com - February 20 at 3:34 PM
Ra Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) StockRa Capital Healthcare Fund Lp Buys 2,500,000 Shares of Ra Pharmaceuticals Inc (RARX) Stock
www.americanbankingnews.com - February 16 at 9:08 PM
Ra Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/ShareRa Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/Share
www.streetinsider.com - February 15 at 4:27 PM
Ra Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceRa Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 8:52 AM
Ra Pharmaceuticals Announces Pricing of Public Offering of Common StockRa Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 14 at 4:41 PM
Ra Pharmaceuticals Announces Proposed Public Offering of Common StockRa Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 14 at 9:02 AM
Ra Pharmaceuticals (RARX) Price Target Cut to $14.00Ra Pharmaceuticals (RARX) Price Target Cut to $14.00
www.americanbankingnews.com - February 13 at 11:44 AM
Ra Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head ReviewRa Pharmaceuticals (RARX) & Pieris Pharmaceuticals (PIRS) Head-To-Head Review
www.americanbankingnews.com - February 10 at 7:24 AM
Ra Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngineRa Pharmaceuticals (RARX) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 3:56 PM
Ra Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by BrokeragesRa Pharmaceuticals Inc (RARX) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 2 at 1:36 AM
Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)Credit Suisse Group Reiterates Outperform Rating for Ra Pharmaceuticals (RARX)
www.americanbankingnews.com - January 21 at 5:34 PM
Zacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per ShareZacks: Brokerages Expect Ra Pharmaceuticals Inc (RARX) Will Announce Earnings of -$0.72 Per Share
www.americanbankingnews.com - January 17 at 5:12 PM
Ra Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in DecemberRa Pharmaceuticals Inc (RARX) Short Interest Up 41.2% in December
www.americanbankingnews.com - January 14 at 2:32 AM
Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal ImpairmentRa Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
finance.yahoo.com - January 8 at 10:56 AM
Analyzing Ra Pharmaceuticals (RARX) and Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) and Its Competitors
www.americanbankingnews.com - January 1 at 9:10 PM
Analyzing Ra Pharmaceuticals (RARX) & Its CompetitorsAnalyzing Ra Pharmaceuticals (RARX) & Its Competitors
www.americanbankingnews.com - December 30 at 5:20 AM
Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis PatientsRa Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
finance.yahoo.com - December 21 at 4:17 PM
Analyzing Ra Pharmaceuticals (RARX) and Its RivalsAnalyzing Ra Pharmaceuticals (RARX) and Its Rivals
www.americanbankingnews.com - December 20 at 9:28 PM
Ra Pharmaceuticals Inc (RARX) Expected to Post Earnings of -$0.72 Per ShareRa Pharmaceuticals Inc (RARX) Expected to Post Earnings of -$0.72 Per Share
www.americanbankingnews.com - December 15 at 3:10 AM
Ra Pharmaceuticals (RARX) versus Its Competitors Head-To-Head ComparisonRa Pharmaceuticals (RARX) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - December 14 at 5:30 AM
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare ConferenceRa Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 11:09 AM
Ra Pharmaceuticals (RARX) vs. The Competition Financial AnalysisRa Pharmaceuticals (RARX) vs. The Competition Financial Analysis
www.americanbankingnews.com - December 6 at 7:52 AM
Ra Pharmaceuticals (RARX) Given "Buy" Rating at Royal Bank Of CanadaRa Pharmaceuticals (RARX) Given "Buy" Rating at Royal Bank Of Canada
www.americanbankingnews.com - December 6 at 12:26 AM
Ra Pharmaceuticals IncRa Pharmaceuticals Inc
www.bloomberg.com - December 5 at 12:28 PM
Why Ra Pharmaceuticals, Inc. Got Hammered TodayWhy Ra Pharmaceuticals, Inc. Got Hammered Today
finance.yahoo.com - December 5 at 12:28 PM
Ra Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital MarketsRa Pharmaceuticals (RARX) Given New $0.00 Price Target at BMO Capital Markets
www.americanbankingnews.com - December 5 at 9:46 AM
Ra Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNHRa Pharmaceuticals (RARX) Reports Positive Interim Results from Phase 2 Study of RA101495 SC in PNH
www.streetinsider.com - December 4 at 4:12 PM
Ra Pharmaceuticals (RARX) Rating Reiterated by BMO Capital MarketsRa Pharmaceuticals (RARX) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - December 4 at 12:30 PM

SEC Filings

Ra Pharmaceuticals (NASDAQ:RARX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ra Pharmaceuticals (NASDAQ:RARX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ra Pharmaceuticals (NASDAQ RARX) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.